Gene · 3269
HRH1: histamine receptor H1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HRH1: histamine receptor H1. Genes, record 3269. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3269
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P35367 | Histamine H1 receptor | 487 | 9 | Ensembl, GeneID, HGNC |
Source UniProt
Patents57
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 49114 | P35367 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 49116 | P35367 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 49117 | P35367 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 11444 | P35367 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 11984 | P35367 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1982 | P35367 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1982 | P35367 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 11984 | P35367 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 11444 | P35367 | Espacenet |
| EP 4440555 A1 | 2024-10-09 | 29 | P35367 | Espacenet |
1 to 10 of 57
See all 57 patentsDrugs113
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ACRIVASTINE | CHEMBL1224 | Histamine H1 receptor antagonist | ANTAGONIST | ChEMBL |
| ALCAFTADINE | CHEMBL1201747 | Histamine H1 receptor antagonist | ANTAGONIST | ChEMBL |
| ANTAZOLINE | CHEMBL1305 | Histamine H1 receptor antagonist | ANTAGONIST | ChEMBL |
| ANTAZOLINE PHOSPHATE | CHEMBL1200550 | Histamine H1 receptor antagonist | ANTAGONIST | ChEMBL |
| ASTEMIZOLE | CHEMBL296419 | Histamine H1 receptor antagonist | ANTAGONIST | ChEMBL |
| AZATADINE | CHEMBL946 | Histamine H1 receptor antagonist | ANTAGONIST | ChEMBL |
| AZATADINE MALEATE | CHEMBL3544908 | Histamine H1 receptor antagonist | ANTAGONIST | ChEMBL |
| AZELASTINE | CHEMBL639 | Histamine H1 receptor antagonist | ANTAGONIST | ChEMBL |
| AZELASTINE HYDROCHLORIDE | CHEMBL1200809 | Histamine H1 receptor antagonist | ANTAGONIST | ChEMBL |
| BEPOTASTINE | CHEMBL1201758 | Histamine H1 receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 113
See all 113 drugsTrials490
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07597473 | AZELASTINE HYDROCHLORIDE | PHASE4 | ClinicalTrials.gov | |
| NCT07575464 | LORATADINE | ClinicalTrials.gov | ||
| NCT07566351 | DESLORATADINE | PHASE2 | ClinicalTrials.gov | |
| NCT07532993 | LORATADINE | PHASE4 | ClinicalTrials.gov | |
| NCT07486583 | DESLORATADINE | PHASE3 | ClinicalTrials.gov | |
| NCT07415278 | AZELASTINE HYDROCHLORIDE | PHASE4 | ClinicalTrials.gov | |
| NCT07381803 | FEXOFENADINE HYDROCHLORIDE | PHASE3 | ClinicalTrials.gov | |
| NCT07358689 | DIPHENHYDRAMINE | PHASE2 | ClinicalTrials.gov | |
| NCT07334002 | BETAHISTINE | ClinicalTrials.gov | ||
| NCT07333716 | DESLORATADINE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 490
See all 490 trialsNIH grants1,218
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HRH1 papers | Newest fiscal year |
|---|---|---|---|
| P30DK056338 | Texas Medical Center Digestive Diseases Center | 7 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| P30DK078392 | Digestive Health Center (DHC): Bench to Bedside Research in Pediatric Digestive Disease | 3 | 2025 |
| ZIADE000721 | Molecular Genetic Studies of Somatosensation | 3 | 2025 |
| IK6BX004601 | BLR&D Research Career Scientist Award | 2 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 2 | 2025 |
| P30CA046934 | University of Colorado Cancer Center Support Grant | 2 | 2025 |
| P30DK123704 | MUSC Digestive Disease Research Core Center | 2 | 2025 |
| P30ES010126 | UNC Center for Environmental Health and Susceptibility | 2 | 2025 |
| P50CA058223 | SPORE in Breast Cancer | 2 | 2025 |
1 to 10 of 1,218Source NIH's project files
See all 1,218 nih grantsPapers3,179
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Antidiabetic Properties of Histamine H1 Receptor Antagonists: A Systematic Review. | Antioxidants (Basel) | 2026 | 42792137 | PubTator, text mining | PubMed |
| Mirtazapine and Slow-Wave Sleep: A Focused Narrative Review of Human Polysomnographic Evidence. | Cureus | 2026 | 42761854 | PubTator, text mining | PubMed |
| Histamine H1 receptor as a potential prophylactic target for COVID-19-induced acute kidney injury during pregnancy. | Kidney Res Clin Pract | 2026 | 42745945 | PubTator, text mining | PubMed |
| GPCR-Driven Muscarinic M1 and Histamine H1 Receptor Signaling Converging on the PI3K/Akt/mTOR Pathway: Functional Integration in Neuroinflammation and Myelin Repair in Multiple Sclerosis. | Mol Neurobiol | 2026 | 42714765 | PubTator, text mining | PubMed |
| Establishment of H1R-SNAP-tag/CMC and screening for anti-allergic active ingredients targeting H1R. | Anal Bioanal Chem | 2026 | 42711560 | PubTator, text mining | PubMed |
| Tape Strip Transcriptomics Reveal Nemolizumab Effects on Pruritus, Hyperplasia, Inflammation, and Extracellular Matrix Markers in Patients With Moderate-to-Severe Atopic Dermatitis. | Allergy | 2026 | 42693785 | PubTator, text mining | PubMed |
| Mast cell-derived histamine negatively regulates hematopoiesis. | Exp Hematol | 2026 | 42692326 | PubTator, text mining | PubMed |
| Virtual Screening, Synthesis and In Vitro Characterization of Histamine H4 Receptor Ligands Based on Pyrimidine Scaffolds. | Int J Mol Sci | 2026 | 42589546 | PubTator, text mining | PubMed |
| Receptor Contribution Reallocation After Removal of Literature-Derived Weights: A Secondary Sensitivity Analysis of the Integrated Ki-DDD-TWAS Pipeline for Antipsychotic Lipid-Trait Prioritization. | Cureus | 2026 | 42540671 | PubTator, text mining | PubMed |
| Preventive Effects of Non-sedating and Sedating Histamine H1 Receptor Antagonists Premedication for Subcutaneous Daratumumab-Associated Infusion-Related Reactions: A Prospective Observational Study. | Biol Pharm Bull | 2026 | 42528221 | PubTator, text mining | PubMed |
1 to 10 of 3,179
See all 3,179 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3269
GET https://conductscience.org/api/genes/v1/3269/patents?page=2